^
Association details:
| Biomarker: | FLT3 wild-type + TP53 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Xospata (gilteritinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
VENETOCLAX AND GILTERITINIB SYNERGIZE IN FLT3 WILDTYPE ACUTE MYELOID LEUKEMIA BY SUPPRESSION OF MCL-1 VIA COMBINED AXL AND FLT3 TARGETING
Published date:
05/12/2022
Excerpt:
Gilteritinib exhibited highest synergy with venetoclax in FLT3 wildtype AML, with especially high synergy values in TP53 mutated samples....The combination of gilteritinib and venetoclax increased apoptosis, reduced viability and abolished colony-formation potential in FLT3 wildtype as well as venetoclax-azacitidine resistant cell lines and primary patient samples….Gilteritinib and venetoclax proved efficacious in an FLT3 wildtype PDX model with TP53 mutation.
